In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

It's the Technology. End of Story

Executive Summary

Over a career that has spanned nearly 40 years, Bob Reiss has built a track record rivaled by few device executives, with senior positions at Sherwood Medical, Alza, Imed, ACS and Interventional Technoloiges. Reiss's most memorable stint: as one of the leaders of ACS, he solved a complex manufacturing problem that helped make angioplasty a common procedure and launched the interventional cardiology revolution. Common to all of Reiss's efforts: the notion that success in medical devices is fundamentally about technology and not, despite the importance of distribution and adoption issues, about marketing.

You may also be interested in...



Two Cheers for Evidence-Based Medicine

In recent years, evidence-based medicine has had an important influence on cardiovascular devices, but it's easy to overlook the staying power of subjective judgment. At a session on "What's the Science on Niche Devices?" held during this year's American Heart Association meeting, the cardiologist-audience clearly didn't seem deterred from using certain devices such as DCA and rotoblators, despite equivical or mediocre results in clinical trials.

Hijacking the Restenosis Market

Innovative device companies have always had to contend with the Sword of Damocles of unexpected technological obsolescence, but for would-be developers of interventional devices for the prevention of restenosis, the sword is dangling perilously close. In the RAVEL trial, a 238-patient clinical trial on a drug eluting stent, treated patients experienced 0% restenosis compared to 26% in the control group. Now, device developers with alternatives to stents reposition themselves to sustain businesses in the face of potentially shrinking target markets. Many argue that they will serve certain applications better than stents; others hope to work with drug-coated stents to enhance performance, many believe that economics will leave room for alternative approaches, and still others are getting out of the coronary business entirely.

Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage

Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. Brian Yang takes a deeper look into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel